Qlaris Bio Announces Positive Topline Data From Two Phase II Trials Of QLS-111 In Patients With Primary Open Angle Glaucoma And Ocular Hypertension QLS-111 met all primary and secondary endpoints in the Osprey and Apteryx studies QLS-111 added to latanoprost drove up...
Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD) VGA039 is potentially the first subcutaneous therapy that addresses all types of VWD and has a convenient dosing regimen SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star...
Recent Comments